How Investigational Product Supply Supports Reliable Clinical Trial Evidence
By Arkadiusz (Eric) Kubik, Ph.D., Clinical Research and Regulatory Science

Clinical trial execution depends on the availability of investigational products and the materials required to manufacture them. While active pharmaceutical ingredients (APIs) provide a medicine's intended pharmacological activity, excipients support the formulation, stability, delivery, and usability of the finished product.
Pharmaceutical supply chains are international and may involve multiple manufacturers, distributors, and suppliers. The sourcing of APIs, starting materials, chemical intermediates, and excipients varies by substance and manufacturer. In some cases, production depends on a limited number of qualified suppliers or specialized manufacturing facilities, leaving few immediate alternatives if a disruption occurs.
Clinical supply planning should account for the time required to qualify alternative sources, assess material specifications, and determine whether a change could affect the investigational product’s formulation or manufacturing process. A second supplier may offer greater sourcing flexibility, but it is not necessarily an immediately available substitute. Sponsors must understand whether alternative materials meet established quality requirements and whether additional testing, documentation, or regulatory assessment would be needed before implementation.
Factor Policy And Trade Shifts Into Sourcing Decisions
Geopolitical developments, trade restrictions, manufacturing interruptions, transportation delays, quality issues, or changes in supplier availability can therefore have consequences beyond commercial production. If an investigational product cannot be manufactured, released, or delivered on schedule, clinical trial activities may be delayed. Participants may need to reschedule visits, sites may face difficulties coordinating treatment schedules, and study timelines may be affected.
U.S. policy discussions concerning pharmaceutical manufacturing resilience and overseas supply-chain dependence reinforce the importance of understanding where critical materials originate and how they move through the supply chain. Legislative initiatives, including the BIOSECURE Act, illustrate how national security and biotechnology-sourcing considerations may influence certain commercial relationships.
The ongoing review of the United States-Mexico-Canada Agreement (USMCA) also presents an opportunity to consider how North American collaboration could contribute to pharmaceutical supply-chain diversification. Expanding regional manufacturing capabilities for APIs, intermediates, and other critical materials could provide additional sourcing options. Greater collaboration among North American partners could therefore be another component of a broader supply-chain resilience strategy. However, regional sourcing would still require appropriate supplier qualification, quality oversight, and assessment of any applicable legal restrictions.
For clinical trials, the value of regional sourcing depends on more than the location of a manufacturing facility. Sponsors must also consider whether materials can be qualified within the study timeline, whether manufacturing capacity is sufficient to support projected enrollment, and how changes in sourcing could affect batch release and investigational product availability. A regional supplier may reduce certain transportation or geopolitical risks without eliminating the need for inventory planning and contingency arrangements.
For clinical research professionals, the practical implication is clear: Reliable clinical evidence depends partly on a reliable supply of the investigational product being evaluated. Supply-chain risks should therefore be considered alongside protocol feasibility, site readiness, and study timelines.
Match Site Supply To Dosing And Blinding Requirements
Once an investigational product reaches a clinical research site, appropriate handling becomes a critical operational and participant-safety responsibility. Site personnel must follow the protocol, sponsor instructions, pharmacy procedures where applicable, and other relevant requirements governing receipt, storage, preparation, dispensing, administration, and accountability.
Product administration may also involve specific technical requirements. Depending on the formulation and protocol, dosing may be based on a fixed amount, body weight, body surface area, or a specified liquid concentration. Research personnel must understand the applicable instructions and ensure that required calculations, preparation steps, and documentation are completed accurately by appropriately qualified staff.
These requirements can also influence the quantity and configuration of investigational product supplied to a site. For example, a weight-based dosing protocol may require different quantities of product as a participant's weight changes over the course of treatment. Supply teams must understand the protocol's dosing requirements, anticipated treatment duration, and available product presentations when estimating site-level inventory. Inadequate forecasting can result in insufficient product for scheduled visits, while excessive supply can increase storage demands and complicate reconciliation.
Blinding adds another layer of complexity. In a blinded study, certain team members must not know which treatment a participant receives, while designated unblinded personnel may need access to treatment information to prepare or dispense the product safely. Responsibilities must be clearly assigned so that product handling does not compromise the study blind or participant safety.
Track Every Unit From Receipt To Reconciliation
Investigational product accountability is equally important. Sites may need to document receipt, storage conditions, dispensing, administration, returns, reconciliation, and disposal according to the study's requirements. Temperature excursions, damaged packaging, discrepancies in inventory, or questions about product integrity must be documented and escalated through the appropriate sponsor or pharmacy channels before affected product is used.
A temperature excursion does not automatically mean that investigational product must be discarded, but the affected inventory should be segregated and placed on hold until its suitability is assessed. The sponsor or designated quality personnel may need to review excursion duration, temperature range, product stability information, and available supporting documentation before determining whether the product can be released for use. Until that determination is communicated, sites must understand which inventory remains available for scheduled participant visits and whether replacement product is needed.
Accountability remains important throughout the study, including at its conclusion. Participants may need reminders to return used and unused study medication at their final visits. Even empty containers may be relevant to product reconciliation, depending on the study's procedures. These records help establish how much investigational product was dispensed, used, and returned, supporting accurate accountability and documentation.
Reconciliation also helps sponsors identify discrepancies between the quantity of product shipped, dispensed, administered, and returned. Differences may require investigation to determine whether they resulted from documentation errors, missed returns, incorrect dispensing records, or other issues. These discrepancies should be resolved according to study procedures before final inventory reconciliation and disposition. Sponsors must also account for the time and logistics required to collect, reconcile, and arrange the appropriate destruction of unused investigational product.
These responsibilities demonstrate how clinical supply management directly supports the integrity of clinical evidence. If product identity, storage, preparation, or administration cannot be reliably established, questions may arise about whether the treatment was handled as intended and how the resulting data should be interpreted.
Resolve Supply Risks Before The First Shipment
Before the first shipment, sponsors and clinical supply teams should confirm that projected inventory accounts for enrollment assumptions, dosing requirements, site activation schedules, and potential resupply lead times. They should also establish procedures for managing temperature excursions, inventory discrepancies, product returns, and changes in supplier availability. These decisions are easier to address before participants begin treatment than after a supply issue threatens scheduled study visits.
Supply planning should also account for the practical realities of site operations. For example, some investigational products require controlled temperature conditions during storage and handling. A refrigerated product may need to be transferred from monitored storage to the treatment area before administration. That transfer must follow the sponsor's specified handling instructions and permitted time limits. If the product is exposed to conditions outside its established requirements, the site should follow the appropriate excursion assessment and escalation procedures rather than assume that the product remains suitable for use. Where necessary, specialized temperature-controlled equipment or validated transfer systems may help maintain the required conditions.
Early review can reveal issues that might otherwise emerge after enrollment begins. A site may need additional equipment, pharmacy support, trained personnel, or clarification about product preparation. Identifying these needs in advance can reduce avoidable delays and help protect participants from scheduling disruptions.
Communication between sponsors, clinical supply teams, pharmacies, investigators, and site coordinators is particularly important when a study involves complex formulations, specialized storage conditions, or products with limited availability. Clear procedures help ensure that problems are escalated promptly rather than handled through assumptions or inconsistent local practices.
Preventing operational problems is not simply an administrative objective. Interruptions can affect participant continuity, protocol adherence, data completeness, and overall study timelines. Effective planning therefore supports both efficient trial execution and the generation of reliable clinical evidence that sponsors may use in regulatory submissions to the FDA.
About The Author:
Arkadiusz (Eric) Kubik is a clinical research and regulatory science professional with a Ph.D. in medical sciences and extensive experience supporting FDA- and Health Canada-regulated clinical trials. He has contributed to more than 50 Phase 1 to 4 studies involving pharmaceuticals and medical devices, with expertise in clinical operations, regulatory compliance, patient safety, and evidence generation. His work integrates biomedical research, toxicology, biomaterials science, and regulatory strategy to advance safe and effective healthcare innovations. Dr. Kubik has collaborated with academic institutions, pharmaceutical sponsors, and leading research organizations as well as hospitals, site management organizations (SMOs), and CROs. He has also shared his expertise with the public through media engagement, including a radio appearance in Chicago, discussing healthcare and scientific topics.